Ignite Creation Date:
2025-12-24 @ 11:24 PM
Ignite Modification Date:
2026-02-01 @ 7:04 PM
Study NCT ID:
NCT02971956
Status:
COMPLETED
Last Update Posted:
2023-09-21
First Post:
2016-11-21
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Pembrolizumab in Refractory Advanced Esophageal Cancer
Sponsor:
Dana-Farber Cancer Institute
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2017-01-18
Start Date Type:
ACTUAL
Primary Completion Date:
2019-07-23
Primary Completion Date Type:
ACTUAL
Completion Date:
2020-05-13
Completion Date Type:
ACTUAL
First Submit Date:
2016-11-21
First Submit QC Date:
None
Study First Post Date:
2016-11-23
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2022-01-18
Results First Submit QC Date:
None
Results First Post Date:
2022-04-08
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-09-07
Last Update Post Date:
2023-09-21
Last Update Post Date Type:
ACTUAL